glp-1 agonist. Frontiers Video: Non-insulin injectable antidiabetic drugs

Diabetologia (2011) 54:96578

2.3.3 GLP-1, inflammation and the gut microbiome In view of the above, increasing evidence indicates a complex and reciprocal relationship among glucagon-like peptide-1 (GLP-1), gut microbiota, and inflammation

The first-in-class dual GIP/GLP-1 RA tirzepatide, available as a once-weekly subcutaneous injection, generates even larger reductions in HbA 1c and weight than semaglutide

Data from the surpass trial series revealed that tirzepatide reduces the risk of major adverse cardiovascular events and improves blood pressure, lipid profiles, and inflammatory markers (60, 61)

[DOI] [PMC free article] [PubMed] [Google Scholar] 49